Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Next Previous
Trial Profile

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avutometinib (Primary) ; Defactinib (Primary) ; Anastrozole; Doxorubicin liposomal; Letrozole; Paclitaxel; Topotecan
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RAMP 301
  • Sponsors Verastem Oncology

Most Recent Events

  • 06 Nov 2024 According to a Verastem Oncology media release, The Company plans to complete enrollment in RAMP 301 by the end of 2025 and company also The Company plans to map out a path forward with the FDA for the KRAS wild-type indication, including the ability to leverage data from the ongoing RAMP 301 Phase 3 trial.
  • 31 Oct 2024 According to a Verastem Oncology media release, this study has the potential to support an expanded indication regardless of KRAS mutation status.
  • 11 Mar 2024 According to a Verastem Oncology media release, a trial-in-progress poster presentation outlining the details of the ongoing Phase 3 RAMP 301 trial will be presented at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women's Cancer, to be held on March 16-18 in San Diego, California.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top